Arizona Cancer Therapeutics is managed by Alliance Therapeutics

JAN 2015.   Arizona Cancer Therapeutics & Barrow's Join Forces on Brain Cancer
ACT has launched a collaborative study with Barrow's Neurological Institute to validate EJ1 drug effectiveness against glioblastoma (brain cancer).  This extensive project is aligned with the company's core values to bring less toxic and highly specific drugs to the clinic for cancer patients.


Scientific Publications
Bitler, B., Menzl, I., Huerta, C.L., Sands, B., Knowlton, W., Chang, A. and Schroeder, J.A. Intracellular MUC1 peptides inhibit cancer progression.  Clinical Cancer Research, 15:100-109, 2009. PMID: 19118037

Horm, T. M., Bitler, B. G., Broka, D., Louderbough, J. M. and Schroeder, J. A. MUC1 Drives c-Met-dependent migration and scattering. Molecular Cancer Research,10:1544-54, 2012. PMID: 23193156

Hart, M.*, Su, H.-Y.*, Broka, D., Goverdhan, A. and Schroeder, J.A. Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression. Molecular Therapeutics, 21:1996-2007, 2013. PMID: 24081029

Media Events
Dr. Schroeder participated in a PBS / Arizona Public Media that aired a breast cancer story (mark 12:05 in the video, Dr. Schroeder's segment begins at mark 19:36) on Friday, October 28, on Arizona Week that follows a breast cancer patient from Douglas, AZ who is being treated at the UACC. The show followed up with the 32-year-old mother of four. She’s a cancer survivor in the process of reconstructive surgery, and hopes she’ll put this chapter behind her one day soon.

2011   Article in Tucson Lifestyle: Cancer Crusader
2012   Article in BizTucson: Joyce Schroeder, Founder of Arizona Cancer Therapeutics
2012   Advertisement in Tucson International Airport for the University of Arizona highlighting our drug development program.
2012   The director of the Office of Public Affairs for the Arizona Board of Regents highlighted my research in a video regarding research being performed at ASU, UA and NAU. Video presented at Regents board meeting.
2013   Highlight is Arizona Business Magazine as 1 of 13 Tech Women to Watch in 2013
2014   AZ Daily Star: UA Researchers Treatment could stop Cancer Metastasis
2015   Daily Wildcat: Cancer Therapy Shows Promise

Patents

Schroeder, Joyce A. (2010) “Therapeutic peptides for the treatment of metastatic cancer”, US Patent 7,767,642 (method of treatment)
Schroeder, Joyce A. (2011) “Therapeutic peptides for the treatment of metastatic cancer”, Australia Patent 2006236441 (method of treatment)
Schroeder , Joyce A. (2012) “Therapeutic peptides for the treatment of metastatic cancer”, US Divisional Patent 8,093,208. (sequence for treatment)
Schroeder, Joyce A. (2012) “Therapeutic peptides for the treatment of metastatic cancer”, Japan Patent 2008-506817 (method of treatment)
Schroeder, Joyce A., Benjamin Bitler and Aarthi Goverdhan (2012) “EGFR-based peptides for the treatment of cancer”, International Patent WO 2012/051247
Schroeder, Joyce A. (2013) “Therapeutic peptides for the treatment of metastatic cancer”, Chinese Patent CN 101977623 (method of treatment)
Schroeder, Joyce A. (2013) “Therapeutic peptides for the treatment of metastatic cancer”, European Patent EP 2247301 (method of treatment)
Schroeder, Joyce A., Benjamin Bitler and Aarthi Goverdhan (2013) “EGFR-based peptides for the treatment of cancer”, US Patent 2013/0252717
Schroeder, Joyce A., Benjamin Bitler and Aarthi Goverdhan (2013) “EGFR-based peptides for the treatment of cancer”, European Patent 2627674
Schroeder, Joyce A., Benjamin Bitler and Aarthi Goverdhan (2013) “EGFR-based peptides for the treatment of cancer”, Japan Patent JP2013544237
Schroeder, Joyce A. (2016) “EGFR-Based Inhibitor Peptides for Combinatorial Inactivation of ErbB1, ErbB2 and ErbB3” PCT/US16/25905​